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Abstract
Aims: Memory impairment in psychosis may be mediated through detrimental effects of 
hypothalamic-pituitary-adrenal (HPA) axis function. This study prospectively investigated 
the relationship between cortisol, sulphate dehydroepiandrosterone (DHEA(S) and 
cortisol:DHEA(S) ratio and memory in 35 first-episode psychosis (FEP) patients during the 
first 12 weeks of treatment and 23 healthy controls (HC). Methods: Morning blood sampling 
and tests of attention, working memory and verbal memory occurred at baseline and 12-week 
follow-up. Results: FEP and HC groups did not significantly differ in levels of cortisol, 
DHEA(S) or their ratio at baseline or over 12-weeks. The FEP group performed significantly 
below HC on all cognitive measures at baseline and over 12-weeks. Cortisol levels were 
unrelated to cognition in both groups. At baseline, DHEA(S) was positively associated with 
attention in HCs, but negatively associated with attention in FEP participants. Change in 
DHEA(S) was negatively associated with change in memory over 12-weeks in both groups. 
At 12-weeks, there was a negative correlation between the cortisol:DHEA(S) ratio and 
attention in both groups. Conclusions: These findings are mostly in contrast to findings in 
chronic schizophrenia. Investigation at different illness phases and over longer-follow-up 
periods is required to determine the complex relationship between HPA-axis and memory 
functioning in psychosis.
Key Words: cortisol; sulphate dehydroepiandrosterone; memory; first-episode psychosis; 
stress
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Abstract
Aims: Memory impairment in psychosis may be mediated through detrimental effects of 
hypothalamic-pituitary-adrenal (HPA) axis function. This study prospectively investigated the 
relationship between cortisol, sulphate dehydroepiandrosterone (DHEA(S) and 
cortisol:DHEA(S) ratio and memory in 35 first-episode psychosis (FEP) patients during the 
first 12 weeks of treatment and 23 healthy controls (HC). Methods: Morning blood sampling 
and tests of attention, working memory and verbal memory occurred at baseline and 12-week 
follow-up. Results: FEP and HC groups did not significantly differ in levels of cortisol, 
DHEA(S) or their ratio at baseline or over 12-weeks. The FEP group performed significantly 
below HC on all cognitive measures at baseline and over 12-weeks. Cortisol levels were 
unrelated to cognition in both groups. At baseline, DHEA(S) was positively associated with 
attention in HCs, but negatively associated with attention in FEP participants. Change in 
DHEA(S) was negatively associated with change in memory over 12-weeks in both groups. At 
12-weeks, there was a negative correlation between the cortisol:DHEA(S) ratio and attention 
in both groups. Conclusions: These findings are mostly in contrast to findings in chronic 
schizophrenia. Investigation at different illness phases and over longer-follow-up periods is 
required to determine the complex relationship between HPA-axis and memory functioning in 
psychosis.
Key Words: cortisol; sulphate dehydroepiandrosterone; memory; first-episode psychosis; 
stress
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1. Introduction
Widespread cognitive impairment is a core characteristic of psychotic disorders that is 
evident at the first episode of psychosis (FEP), with prominent deficits observed in 
information processing speed, executive functioning and verbal memory (Mesholam-Gately 
et al., 2009). Emergence of cognitive impairment occurs well before the onset of the first 
psychotic episode, even in early childhood (Fusar-Poli et al., 2012), suggesting aberrant 
neurodevelopment (Bora and Murray, 2014). Cognitive impairments generally remain 
relatively stable for many years after the first episode (Bozikas and Andreou, 2011). 
Longitudinal studies have shown that relative to other cognitive domains, poor verbal 
memory is particularly associated with poorer clinical outcomes, such as incomplete 
symptomatic recovery and relapse (Barder et al., 2013; Benoit et al., 2014; Bozikas and 
Andreou, 2011; Chang et al., 2013). Impaired verbal memory is also a significant predictor of 
poorer long-term functional outcomes in both clinical high-risk (Lin et al., 2011) and first-
episode cohorts (Chang et al., 2013).
The neurobiological mechanisms mediating memory impairment in psychotic 
disorders are not clearly understood. Cognitive function, particularly learning and memory, is 
known to be sensitive to stress (Aas et al., 2011; Teicher et al., 2002). Elevated stress or 
chronic exposure to stress can lead to dysfunction of the hypothalamic-pituitary-adrenal 
(HPA) axis in vulnerable individuals (Lupien et al., 2009). The HPA-axis regulates both 
neuroendocrine (i.e., glucocorticoid release) and behavioural stress responses (Smith and 
Vale, 2006). Levels of cortisol, a glucocorticoid hormone released from the adrenal gland in 
response to stress, is a common measure of HPA-axis activity. Dehydroepiandrosterone 
(DHEA) and its sulphate form DHEA(S) are neurosteroids produced by the adrenal gland that 
exert anti-glucocorticoid effects. In this regard, DHEA represents additional neurosteroid 
mechanisms that are of relevance to the regulation of the HPA-axis (Crowley and Girdler, 
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2014). DHEA(S) is released together with cortisol in response to stress and is known to 
counteract the negative effects of cortisol in the brain (Kimonides et al., 1999), exerting 
neuroprotective properties (Wolkowitz et al., 2001). Under conditions of chronic stress, 
DHEA(S) levels decline (while cortisol levels are maintained), resulting in an elevated 
cortisol:DHEA(S) ratio (Wolkowitz et al., 2001). It has been suggested that this may result in 
attenuated buffering of the cognitive-impairing effects of cortisol (Maninger et al., 2009).
Prolonged exposure to elevated levels of cortisol is shown to have detrimental effects 
on the structural and functional integrity of the brain, particularly involving hippocampal 
atrophy and memory impairment, respectively. Studies in rats have shown that chronic 
exposure to stress or corticosterone (the rodent equivalent of cortisol) leads to atrophy of 
dendrites in the hippocampus (Watanabe et al., 1992), which is accompanied by impaired 
performance on hippocampal-dependent memory tasks (Luine et al., 1994). A relationship 
between cortisol, the hippocampus and memory function has been demonstrated across a 
range of human conditions, treatment with steroids, normal aging, and stress-related 
psychiatric disorders (Corcoran et al., 2003; Sapolsky, 2000; Walder et al., 2000). 
Furthermore, higher DHEA(S) levels in military personnel predicted superior cognitive 
performance under stress (Morgan et al., 2009). A higher cortisol:DHEA(S) ratio is 
associated with cognitive decline (Kalmijn et al., 1998), and poorer visuospatial memory 
performance in healthy older adults (van Niekerk et al., 2001), and higher distraction during a 
working memory task in healthy female adults (do Vale et al., 2014). Following anti-
glucocorticoid treatment (decreasing cortisol levels), an increase in hippocampal volume and 
improvement in memory is observed (Starkman et al., 2003), indicating that cortisol-induced 
memory deficits may be reversible. While DHEA(S) supplementation has been shown to 
have cognitive (working memory) enhancing properties in rodents (Maninger et al., 2009; 
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Wolf and Kirschbaum, 1999), clinical trials of DHEA(S) in healthy older adults have 
produced conflicting findings (Huppert et al., 2000).
HPA-axis hyperactivity is often reported in schizophrenia populations (Corcoran et 
al., 2003), including elevated plasma cortisol and adrenocorticotropic hormone levels 
(Lammers et al., 1995; Ryan et al., 2004), and increased corticotropic-releasing hormone 
concentrations in cerebrospinal fluid (Banki et al., 1987). HPA hyperactivity may be 
potentiated by attenuated negative feedback inhibition of HPA function in schizophrenia 
(Lammers et al., 1995). In particular, impairments in hippocampal-mediated suppression of 
HPA function may play a key role. Studies have reported an inverse correlation between 
cortisol levels and performance on hippocampal-dependent memory tasks (Newcomer et al., 
1998; Walder et al., 2000) and a positive correlation between circulating DHEA(S) and 
memory performance (Harris et al., 2001; Silver et al., 2005) in chronic schizophrenia. 
Clinical trials of DHEA augmentation in people with chronic schizophrenia have reported a 
non-significant improvement in memory (Strous et al., 2007) and found DHEA(S) levels to 
be a positive predictor of cognitive functioning (Ritsner and Strous, 2010). 
The initial psychotic phase may also be associated with dysregulation of the HPA-
axis, although fewer studies have been conducted and findings have been mixed. For 
example, studies have found elevated levels of circulating adrenocorticotropic hormone and 
cortisol (Ryan et al., 2004), reduced cortisol levels (Phassouliotis et al., 2013), and no 
difference between FEP and healthy controls groups in levels of cortisol, DHEA(S) or their 
ratio (Garner et al., 2011). However, in the latter study decreases in cortisol and the 
cortisol:DHEA(S) ratio over 12 weeks were associated with improvements in depression and 
psychotic symptoms (Garner et al., 2011). The relationship between stress hormones and 
memory function in early psychosis has received limited investigation and analyses have 
been cross-sectional. One study found that blunted (i.e., abnormal) cortisol levels following 
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awakening were associated with more impaired verbal memory and processing speed in FEP 
(Aas et al., 2011). In contrast, Labad et al. (2016) found that an increased cortisol awakening 
response was associated with poorer verbal memory and processing speed and a more 
flattened diurnal cortisol slope was associated with poorer visuospatial working memory in 
females with early psychosis. Dexamethasone suppression ratio was associated with better 
visual memory in both males and females (Labad et al., 2016). In another study, higher 
afternoon cortisol levels at treatment entry were significantly related to impaired verbal 
memory performance at in hospitalized males with first-episode schizophrenia (Havelka et 
al., 2016).
  As poor verbal memory is present at the first episode of psychosis and associated 
with a poorer illness course, the relationship between stress hormones and memory in early 
psychosis is a critical area of investigation. The current study aimed to investigate the 
relationship between circulating stress hormones (cortisol, DHEA(S) and their ratio) and 
verbal memory function prospectively in people with FEP during the initial 12 weeks of 
treatment, compared to healthy controls. To our knowledge this is one the first studies to 
prospectively investigate stress hormones and cognitive functioning in drug-naïve or 
minimally-treated FEP patients compared to sex and age-matched healthy control 
participants. We hypothesised that higher cortisol, lower DHEA(S) and a higher 
cortisol:DHEA(S) ratio would be associated with poorer verbal memory performance in 
minimally-treated FEP patients and healthy controls at baseline and 12-weeks follow-up. We 
also explored whether a reduction in the cortisol:DHEA(S) ratio during the initial 12 weeks 
of treatment would correlate with improved memory performance in the FEP group at the 12-
week follow-up assessment. 
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2. Methods
2.1 Participants
Participants for the current study came from an overarching study examining stress and 
HPA-axis functioning in FEP and the relationships with clinical, cognitive and brain structure 
variables (Garner et al., 2011; Phassouliotis et al., 2013; Reniers et al., 2015). Neuroleptic-
naïve or minimally-treated FEP patients were recruited from the Early Psychosis Prevention 
and Intervention Centre (EPPIC) at Orygen Youth Health, Melbourne, Australia. Inclusion 
criteria were based upon the entry criteria for EPPIC as follows: aged 15-25 years, 
experiencing a first episode psychotic disorder as per DSM-IV criteria, and resident in the 
EPPIC catchment (North/North-Western suburbs of metropolitan Melbourne). Exclusion 
criteria were >10 days of treatment with any psychotropic medication, IQ<70, neurological or 
brain impairment, any significant medical illness including impaired thyroid function, 
polydipsia, asthma, diabetes or chronic fatigue syndrome, steroid medications, and shift 
work. Females taking an oral contraceptive were also excluded due to potential interactions 
between oral contraceptives and androgen levels. Participants received standard EPPIC 
treatment over the 12-week study period, including low dose antipsychotic medication and 
intensive case management and psychosocial rehabilitation.
Healthy control (HC) participants were recruited from similar socio-demographic areas 
through advertisements and acquaintances of the FEP participants. Exclusion criteria 
included a current or past history of psychiatric illness or any psychiatric illness in the 
immediate family, in addition to the exclusion criteria described for the FEP group. Details of 
the previous two menstrual cycles were recorded for all female participants, however as we 
previously found no differences between menstrual cycle phase and biological stress 
measures (Garner et al., 2011) these were not included in the current analysis. The study was 
approved by the Melbourne Health Human Research and Ethics Committee. After complete 
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description of the study, written informed consent was obtained from participants or a parent 
or guardian when appropriate.
2.2 Clinical Assessments conducted at Baseline
To confirm inclusion the patient edition of the Structured Clinical Interview for DSM-
IV for Axis I disorders (SCID-I/P) was administered to FEP participants and the Structured 
Clinical Interview for DSM-IV Non-Patient edition (SCID-I/NP) was administered to control 
participants. The Perceived Stress Scale (PSS) (Cohen et al., 1983) was used to examine 
subjective levels of stress in both groups. Body mass index and tobacco use in the previous 
month were collected. The following clinical assessments were also completed with FEP 
participants only: Brief Psychiatric Rating Scale extended version 4 (BPRS) (Ventura et al., 
1993), Scale for the Assessment of Negative Symptoms (SANS) (Andreasen, 1989) and 
Social and Occupational Functioning Scale (SOFAS) (Goldman et al., 1992). The BPRS 
positive symptom subscale (BPRS-P) consisted of the 4 core psychotic items: suspiciousness, 
hallucinatory behaviour, disorganised thinking and unusual thought content. 
2.3 Blood Collection and Analyses
Blood sampling occurred between 9.00 and 10.00am upon entry to the study and at 12 
weeks follow-up. Blood (20mL) was withdrawn by venepuncture into tubes containing SST 
or EDTA for the collection of serum and plasma, respectively. Serum cortisol levels were 
analysed by Gribbles Pathology (Melbourne, Australia) and plasma DHEA(S) levels were 
analysed by Melbourne Pathology (Melbourne, Australia). DHEA(S) was measured, as 
opposed to DHEA, because it is more stable with a longer half-life and less prone to changes 
with the circadian rhythm (Wolf and Kirschbaum, 1999). 
2.4 Cognitive Assessment
Assessment of attention, working memory and verbal learning and memory was 
performed with both groups at baseline and 12 weeks. The cognitive assessment was 
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conducted as close to the time of blood sampling as possible. The Wide Range Achievement 
Test-Third Edition (WRAT-3)-Reading subtest was administered at baseline to estimate 
premorbid IQ. The Digit Span - digits forward subtest from the Wechsler Adult Intelligence 
Scale – Third Edition (WAIS-III) was used as a measure of immediate auditory-verbal 
attention span. Digit Span - digits backward and Letter-Number Sequencing total score from 
the WAIS-III were used to measure auditory verbal working memory. Verbal learning and 
memory was assessed using an experimental verbal paired associate learning (PAL) test 
based on a paradigm used by Savage et al. (2002), which demonstrated sensitivity to 
dysfunction in medial temporal lobe structures. Individuals with chronic schizophrenia have 
demonstrated impaired performance on the task (Gallucci et al., 2001) and the current version 
of the task was designed to load minimally on attention and working memory. The task 
involves initial pre-learning of two lists of 8 words over 3 trials of exposure and free recall, 
followed by 3 trials of exposure and cued recall for 8 inter-list arbitrary pairings of the words. 
The imageability of the words varied across pairs (e.g., ‘horse-forest’, ‘busy-limit’). Cued 
recall of the word pairs was tested after a 20-minute delay. Alternate versions of the test were 
used at the two time points to minimise practice effects. All tests were administered and 
scored according to standardised instructions, and raw scores were used in the analysis. 
2.5 Statistical Analysis
Independent-samples t-tests were used to compare the two groups with respect to 
baseline stress hormones and cognitive measures. Repeated-measures analysis of variance 
(ANOVA) with a group factor (FEP and HC) and a time factor (baseline and week 12) was 
used to examine change in stress hormone levels and cognitive performance from baseline to 
12 weeks. To investigate whether stress hormone levels were associated with attention, 
working memory and learning and memory performance, general linear model analysis was 
employed with each of the cognitive measures as the dependent variable in turn, and each of 
ALLOTT et al.      11
the stress hormone measures as the independent variable in turn. The analysis was carried out 
on the combined sample with age and sex as covariates (as stress hormones can differ based 
on age and sex (Wudy et al., 2007)) to examine the general relationship between stress 
hormones and cognitive performance. The group factor (FEP and HC) was also included. 
This was to allow the examination of the group by stress hormone interaction, which would 
indicate whether there were any differences between the FEP and HC group in the 
relationship between stress hormones and cognitive performance. We also examined explored 
if the results changed after adjusting for premorbid IQ (presented in Supplementary Tables; 
caution in interpreting these tables is recommended because measurement of premorbid IQ 
based on a reading test may be problematic in adolescents and young adults who are yet to 
complete their education and whose education will have been disrupted due to their 
psychosis). The group factor (FEP and HC) was also included. This was to allow the 
examination of the group by stress hormone interaction, which would indicate whether there 
were any differences between the FEP and HC group in the relationship between stress 
hormones and cognitive performance. The analysis was conducted using the relevant baseline 
values, week 12 values and the change in values (week 12 minus baseline). Alpha-level was 
set at .05. There was no adjustment for multiple comparisons because such correction is only 
required when carrying out joint hypothesis testing (Rothman et al., 2008), and this was not 
our aim. IBM SPSS Statistics 22 and S-PLUS 6.1 were used to conduct the analyses.
3. Results
3.1 Sample Characteristics at Baseline
Thirty-five FEP and 23 HC participants were included in the current study. Table 1 
shows the baseline characteristics of the two groups. The FEP participants were significantly 
younger and had a lower level of education and estimated premorbid IQ compared to the 
HCs. FEP participants also reported significantly higher levels of perceived stress and were 
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more likely to have used tobacco in the previous month. DSM-IV diagnoses of FEP 
participants were: schizophreniform disorder (n=15), schizoaffective disorder (n=2), 
delusional disorder (n=1), psychotic disorder NOS (n=3), bipolar disorder I with psychotic 
features (n=1), major depressive disorder with psychotic features (n=4), substance-induced 
psychotic disorder (n=2), and specific psychotic diagnosis was unavailable for 7 participants 
who were unable to complete the SCID, but had a confirmed ‘first-episode psychosis’ 
according to clinical notes. Among the FEP participants, prior to baseline blood collection 12 
were prescribed antipsychotic medication, 9 were neuroleptic naïve and 14 had missing 
information. Of the 12 who were taking medication, the mean number of days on 
antipsychotics prior to baseline blood collection was 4.3 (SD 1.5, minimum 2, maximum 7).
3.2 Change in Stress Hormone Levels and Cognitive Performance over 12 weeks
For the FEP group, the time difference between the baseline blood sampling and 
cognitive assessment ranged from 1 to 15 days, with 47% being conducted within 4 days. For 
the control group, the two procedures were conducted within 0 to 9 days, with 91% being 
within 4 days. Table 2 shows the results for levels of cortisol, DHEA(S) and the 
cortisol:DHEA(S) ratio at baseline and 12 weeks. No significant differences were found 
between the two groups on any of the stress hormone measures at baseline. There were no 
significant changes in any of the stress hormone levels from baseline to 12 weeks in either 
group (cortisol p=.770; DHEA(S) p=.167; cortisol:DHEA(S) p=.449), nor were there any 
group by time interactions (cortisol p=.993; DHEA(S) p=.227; cortisol:DHEA(S) p=.535).
Table 3 shows the cognitive performance of the two groups at baseline and 12 weeks. 
At baseline, the FEP participants performed more poorly on all cognitive tasks relative to the 
HC group, with effect sizes in the medium to large range. Repeated-measures ANOVA 
indicated there was a significant main effect of time (i.e., change between baseline and 12 
weeks) for performance on digit span backwards, which improved over 12 weeks (p=.045) 
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and immediate paired associate learning, which worsened over 12 weeks (p=.019). There 
were no significant effects of time on the other cognitive measures. There were no significant 
group by time interactions for any of the cognitive measures (all p>.05). 
3.3 Relationship between stress hormone levels and cognitive functioning
3.3.1 Baseline
There were no significant relationships between cognitive performance and stress 
hormone levels at baseline (all p>.05; Supplementary Table). There was a significant group 
by DHEA(S) interaction for digit span forward (immediate attention) (p=.0493), showing that 
higher DHEA(S) was associated with better performance in HC (r=.41), but poorer 
performance in the FEP group (r=-.1622) (Figure 1).
3.3.2 Follow-up (12 weeks)
There was a significant negative relationship between digit span forward (immediate 
attention) and the cortisol:DHEA(S) ratio (partial r=-.42; p=.02) at 12 weeks. There were no 
significant group by stress hormone interactions in association with cognitive performance 
(all p>.05; Supplementary Table).
3.3.3 Change in stress hormone levels and cognitive performance over 12 weeks
 The relationship between change in stress hormones and cognitive performance over 
12 weeks (week 12 minus baseline) was explored. There was a negative association between 
changes in DHEA(S) and immediate paired associate learning (partial r=-.43; p=.025) over 
12 weeks, such that increased levels of DHEA(S) was associated with worsening of paired 
associate learning. There were no significant group by stress hormone interactions (all p>.05; 
Supplementary Table).
4. Discussion
Understanding how stress and HPA-axis (dys)function are associated with the course 
of early psychosis could have important implications for the development of therapeutic 
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interventions that can target the HPA-axis and cognitive sequelae. To our knowledge, this is 
the first prospective study to investigate the longitudinal relationship between circulating 
stress hormones (cortisol, DHEA(S)) and cognitive performance in people with FEP during 
the initial 12 weeks of treatment, compared to healthy controls. The key findings can be 
summarised as follows: (1) At baseline the FEP and HC groups did not differ in levels of 
cortisol, DHEA(S) or their ratio and no significant group differences were observed in the 
change of these hormone concentrations over the 12-week follow-up. (2) Consistent with 
previous research (Mesholam-Gately et al., 2009), the FEP group performed significantly 
below HC on all cognitive measures at baseline. While working memory improved and 
immediate paired associate learning declined over 12 weeks in the overall group, there were 
no significant group differences in change in cognitive performance over this period. (3) 
Cortisol levels were not related to memory or other cognitive performances in either group. 
(4) Baseline DHEA(S) was associated with baseline attention span (digit span forward). 
Specifically, higher DHEA(S) was positively associated with attention scores in HCs, but 
negatively associated with attention in FEP individuals (Figure 1). Further, change in 
DHEA(S) was negatively associated with change in immediate paired associate learning over 
the 12-week period in both groups. (5) At 12 weeks, there was a negative correlation between 
the cortisol:DHEA(S) ratio and attention (digit span forward) in both groups. (6) Exploration 
of the relationship between changes in the cortisol:DHEA(S) ratio during the initial 12 weeks 
of treatment and memory performance in FEP yielded nonsignificant findings. 
Previous studies have demonstrated associations between stress hormone levels and 
memory (and other cognitive) functioning in people with psychosis. Higher cortisol has been 
associated with poorer memory in medicated chronic schizophrenia samples (Newcomer et 
al., 1998; Walder et al., 2000). In FEP studies, higher afternoon cortisol levels have been 
associated with poorer verbal memory (Havelka et al., 2016), and both blunted (Aas et al., 
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2011) and increased (Labad et al., 2016) awakening cortisol responses have been associated 
with poorer memory and processing speed. In contrast, cortisol levels were not associated 
with cognitive functioning in either group in the current study. In Walder et al. (2000), 
cortisol was measured hourly over three hours and the strongest negative association between 
memory performance and cortisol was evident at hour three. A study by Silver et al. (2005) 
found no relationship between memory performance and a single morning blood cortisol 
level in a schizophrenia sample. Given previous research in FEP has suggested a blunted 
awakening cortisol response in the context of increased cortisol levels throughout the day 
(Mondelli et al., 2010), it is possible that our single morning measurement did not adequately 
capture the likely complex relationship between cortisol and memory in FEP (also see Aas et 
al., 2011; Labad et al., 2016). Thus, frequency and timing of blood sampling may partly 
explain these different findings. Furthermore, the largest study in FEP to date by Labad et al. 
(2016) found that the relationship between cortisol awakening response and cognitive 
performance was evident only in women, highlighting sex as an important moderating factor. 
Additionally, Newcomer et al. (1998) found that dexamethasone treatment (a synthetic 
glucocorticoid) did not decrease verbal memory performance in people with schizophrenia, 
although it did in HCs, suggesting reduced functional (brain) sensitivity to acute effects of 
cortisol in schizophrenia. 
Lower DHEA(S) has also been associated with poorer cognition in medicated chronic 
schizophrenia samples (Harris et al., 2001; Ritsner and Strous, 2010; Silver et al., 2005). In 
this FEP study at baseline, the hypothesised positive relationship between DHEA(S) and 
attention was observed in HC, whereas a negative association was evident in the FEP group. 
Thus, despite similar levels in both groups, DHEA(S) did not have a positive relationship 
with attention span in this FEP sample. Also unexpectedly, a higher cortisol:DHEA(S) ratio 
was associated with better attention span at 12 weeks in both groups. Our findings are in 
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contrast to previous research in chronic schizophrenia, which found that circulating DHEA(S) 
was positively associated with sustained attention (explaining 6.9% variance) (Ritsner and 
Strous, 2010), memory (r=.42-.51) (Harris et al., 2001; Silver et al., 2005) and executive 
functioning (r=.50) (Silver et al., 2005). Furthermore, the cortisol:DHEA(S) ratio was 
previously found to be negatively associated with visual memory and executive functioning 
(explaining 3.7% and 3.6% variance, respectively) (Ritsner and Strous, 2010). Interestingly, 
change in DHEA(S) was negatively associated with change in immediate paired associate 
learning over the 12-week period in both groups, that is, an increase in DHEA(S) over time 
was associated with a decrease in memory performance. Again, this finding was unexpected 
and in contrast to previous research in chronic schizophrenia (Ritsner and Strous, 2010). It is 
important to note that DHEA levels were not measured in the current study, thus the 
possibility of altered DHEA in the FEP individuals and an association with cognitive 
performance cannot be ruled out. 
Compared to the current sample, these previous chronic schizophrenia studies 
reported much lower DHEA(S) levels and a higher cortisol:DHEA(S) ratio, likely indicative 
of phase of illness (mean length of illness 13-14 years) and/or age (mean 36-48 years) of 
participants (Harris et al., 2001; Ritsner and Strous, 2010; Silver et al., 2005). Chronic 
patients may show a large variation in HPA function due to long-term medication and more 
variable degrees of exposure to stress, whereas in FEP there is a much shorter duration of 
treatment and illness. These factors may moderate the relationship between neurosteroids and 
cognition in psychosis. Given that FEP participants had hormone levels within the range of 
HCs, it could be argued that the stress related to the onset of illness (as well as previous stress 
exposure) was not ‘chronic enough’ (given it is still very early on in the course) to cause 
significant long-lasting down-regulation of DHEA(S). Indeed, their cortisol levels were not 
abnormally high or low relative to HCs. It has also been previously suggested that a lack of a 
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group difference and relative stability in stress hormone levels over 12 weeks in FEP and 
HCs may be indicative of an absence of a neurosteroid response to the initial stage of 
psychosis in the FEP participants (Garner et al., 2011). Longitudinal studies that include 
measures of chronic stress, such as hair cortisol levels will be more informative.
The relative stability of cognitive impairment in the FEP group over the follow-up 
period is consistent with previous research and perhaps unsurprising given that 12 weeks is a 
relatively short period to expect significant cognitive change. Most studies that have shown 
cognitive improvement following FEP (over and above practice effects) had follow-up 
periods of 1 year or longer (Bora and Murray, 2014; Bozikas and Andreou, 2011). Poorer 
verbal memory at baseline has been associated with a diagnosis of schizophrenia relative to 
affective psychoses (Zanelli et al., 2010), a lack of symptomatic remission (Benoit et al., 
2014; Chang et al., 2013), and early psychotic relapse (Barder et al., 2013) in FEP, but in 
these studies marked memory impairment was evident early, without significant memory 
decline thereafter (Benoit et al., 2014; Chang et al., 2013). In order to better understand the 
neurobiological mechanisms (such as HPA-axis function) associated with memory 
impairment or decline, subgroup-level analyses of those with the poorest outcomes may be 
needed. This should also include further longitudinal research in those at clinical high risk for 
psychosis given memory impairment usually emerges before the first psychotic episode 
(Fusar-Poli et al., 2012). 
Strengths of this study include recruitment of a carefully selected minimally-treated 
FEP sample and prospective observation over the initial treatment period, including repeat 
cognitive assessment. There are also limitations that warrant mentioning. The sample size 
could be considered relatively small, though it is larger than many previous studies (Aas et 
al., 2011; Harris et al., 2001; Havelka et al., 2016; Newcomer et al., 1998; Silver et al., 2005; 
Walder et al., 2000) and it is worth noting that recruiting and retaining minimally-treated 
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unwell FEP participants is challenging. For the main aim of this study, which was to examine 
whether the relationship between stress hormones and verbal memory function differ between 
FEP individuals and healthy controls, a sample size of about 110 would be needed to explain 
a large effect (for 80% power and 5% significance level). Thus, lack of power could be a 
possible reason for some of the non-significant findings. Furthermore, given the small 
sample, separate analysis on males and females could not be conducted and would have been 
preferable to statistically controlling for sex. Second, measurement of stress hormone levels 
at one time point is likely to be less reliable than the diurnal rhythm. Time of awakening was 
not recorded in the current study, which may have been a potential confounder. Possible 
group differences in diurnal stress hormone levels that have been previously shown in FEP 
(Aas et al., 2011; Mondelli et al., 2010) may have been present. Assessment of hormone 
levels after blood sampling might have been confounded by the anticipatory stress of the 
venipuncture procedure and perceived stressfulness of blood-taking was not 
assessed. Furthermore, as blood samples were often not taken on the same day as the 
cognitive assessment this may have affected the relationships observed. Nevertheless, it is 
important to note that stress hormone levels remained quite stable in both groups over the two 
time-points. Additionally, the FEP participants had a range of psychosis diagnoses and for 
some the diagnosis was unknown. Thus, apart from the short follow-up period, the chances of 
detecting significant relationships may have been reduced due to heterogeneous clinical 
presentations. The treatment received over the 12-week period was not recorded and 
therefore could not be taken into account in the analysis (e.g., effect of antipsychotics on 
neuroendocrine markers). Finally, administration of the cognitive tasks (including the 
alternate forms of the PAL task) between time-points was not counter-balanced to minimise 
possible order effects; this may have explained the decline in immediate paired associate 
learning in both groups over the 12 week period.
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While we observed some significant relationships between stress hormones and 
cognitive performances in FEP and HCs, most observations were non-significant or in the 
unexpected direction. In particular, the findings of the current study suggest a possible 
relationship between DHEA(S) and attention and immediate paired associate learning over 
the first 12 weeks of treatment in FEP. This study supports the need for the inclusion of 
neurobiological markers such as stress-related hormones in neuropsychological research. 
Further investigation with larger samples, at different phases of illness, and over longer 
follow-up periods is needed to determine the likely complex relationship between HPA-axis 
and memory functioning in psychosis.
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Table 1. Baseline characteristics of the two groups.
FEP (n=35) HC (n=23) p-value*
Age (mean, SD) 20.3 (2.5) 22.1 (1.8) 0.002
Sex (n, % male) 26 (74.3) 18 (78.3) >0.999
Education (n, % completed Year 12) 14 (40.0) 22 (95.7) <.001
Premorbid IQ (mean, SD) 95.6 (11.7)b 102.6 (11.0) 0.032
Body Mass Index (mean, SD) 24.0 (6.1)c 21.7 (3.3) 0.090
Tobacco use in past month (n, % yes) 24 (70.6)d 5 (22.7)e 0.001
PSS total (mean, SD) 33.8 (8.5)a 22.0 (6.5) <.001
BPRS psychotic subscale (mean, SD) 15.0 (4.2)b
SANS total (mean, SD) 21.7 (12.5)b
SOFAS (mean, SD) 55.2 (9.6)
FEP=first-episode psychosis; HC=healthy controls; SD=standard deviation; PSS=Perceived Stress 
Scale; BPRS=Brief Psychiatric Rating Scale; SANS=Scale for the Assessment of Negative 
Symptoms; SOFAS=Social and Occupational Functioning Scale
*Age, premorbid IQ, Body Mass Index, PSS Total: t-test p-value; sex, education, tobacco use: 
Fisher’s exact test p-value.
an=30; bn=31; cn=29; dn=34; en=22
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Table 2. Cortisol, DHEA(S) and their ratio at baseline and 12 weeks.
FEP HC p-
value
Cortisol (nmol/L; mean, SD) Baseline 486.4 (137.3) 479.9 (132.8) 0.860
12 weeks 494.2 (114.7) 488.1 (107.3)
DHEA(S) (nmol/L; mean, SD) Baseline 9340.6 (2735.8) 8839.1 (3785.1) 0.591
12 weeks 11147.4 (3518.7) 8856.2 (3723.3)
Cortisol:DHEA(S) ratio (mean, 
SD)
Baseline 5.6 (2.3) 6.5 (3.1) 0.281
12 weeks 4.9 (4.2) 6.4 (2.8)
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Table 3. Cognitive functioning at baseline and 12 weeks.
FEP HC p-
value*
Effect 
Size
Attention
Digit span forward (raw) Baseline 9.3 (2.5) 10.9 (2.3) .015 0.63
12 weeks 10.3 (2.1) 11.8 (2.1)
Working Memory
Digit span backward (raw) Baseline 5.4 (1.7) 8.7 (2.6) <.001 1.24
12 weeks 6.4 (2.3) 9.4 (1.9)
Letter number sequencing (raw) Baseline 9.2 (3.5) 12.1 (2.8) .001 0.81
12 weeks 10.1 (2.6) 12.6 (1.3)
Verbal Learning and Memory
Immediate PAL totala Baseline 15.3 (7.3) 22.9 (3.8) <.001 1.07
12 weeks 13.3 (4.4) 19.0 (3.7)
Delayed PAL totalb Baseline 4.7 (2.4) 7.2 (1.0) <.001 1.08
12 weeks 4.9 (2.4) 6.2 (1.8)
*t-test p-value; PAL=paired associate learning; aMaximum score=24; bMaximum score=8
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Figure Legend
Figure 1. Baseline digit span forward by DHEA(S) for each group.
C=Control
F=FEP
DHEAS=sulphate dehydroepiandrosterone
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Figure 1. Baseline digit span forward by DHEA(S) for each group.
1Supplementary Tables
P values for primary analysis and when premorbid IQ is added as a covariate.
Baseline
Cognitive Test Hormone Adjusting 
for 
group, 
age, sex
Group x 
Stress 
hormone 
interaction
Adjusting 
for 
premorbid 
IQ
Group x 
sex 
interaction 
adjusting 
for 
premorbid 
IQ
Attention
Digit span forward 
(raw)
Cortisol 0.904 0.055 0.712 0.014
DHEAS 0.639 0.049 0.433 0.002
Cortisol:DHEAS 0.798 0.707 0.290 0.185
Working Memory
Digit span 
backward (raw)
Cortisol 0.122 0.611 0.617 0.986
DHEAS 0.114 0.698 0.165 0.234
Cortisol:DHEAS 0.964 0.516 0.545 0.119
Letter number 
sequencing (raw)
Cortisol 0.356 0.069 0.078 0.018
DHEAS 0.978 0.301 0.516 0.251
Cortisol:DHEAS 0.702 0.916 0.101 0.769
Verbal Learning and Memory
Immediate PAL 
total
Cortisol 0.378 0.634 0.250 0.289
DHEAS 0.987 0.587 0.541 0.406
Cortisol:DHEAS 0.286 0.902 0.766 0.235
Delayed PAL total Cortisol 0.813 0.420 0.744 0.588
DHEAS 0.746 0.309 0.304 0.383
Cortisol:DHEAS 0.644 0.422 0.232 0.071
PAL=paired associate learning; DHEAS=sulphate dehydroepiandrosterone
212 Weeks
Cognitive Test Hormone Adjusting 
for 
group, 
age, sex
Group x 
Stress 
hormone 
interaction
Adjusting 
for 
premorbid 
IQ
Interaction 
adjusting 
for 
premorbid 
IQ
Attention
Digit span forward 
(raw)
Cortisol 0.058 0.736 0.178 0.975
DHEAS 0.290 0.689 0.114 0.273
Cortisol:DHEAS 0.020 0.754 0.008 0.211
Working Memory
Digit span 
backward (raw)
Cortisol 0.131 0.314 0.350 0.388
DHEAS 0.453 0.088 0.607 0.006
Cortisol:DHEAS 0.531 0.457 0.480 0.035
Letter number 
sequencing (raw)
Cortisol 0.669 0.585 0.940 0.499
DHEAS 0.829 0.495 0.549 0.389
Cortisol:DHEAS 0.484 0.969 0.207 0.923
Verbal Learning and Memory
Immediate PAL 
total
Cortisol 0.403 0.610 0.689 0.797
DHEAS 0.517 0.676 0.574 0.995
Cortisol:DHEAS 0.713 0.883 0.692 0.469
Delayed PAL total Cortisol 0.667 0.175 0.924 0.155
DHEAS 0.903 0.562 0.659 0.393
Cortisol:DHEAS 0.431 0.527 0.304 0.378
PAL=paired associate learning; DHEAS=sulphate dehydroepiandrosterone
3Change over 12 weeks
Cognitive Test Hormone Adjusting 
for 
group, 
age, sex
Group x 
Stress 
hormone 
interaction
Adjusting 
for 
premorbid 
IQ
Interaction 
adjusting 
for 
premorbid 
IQ
Attention
Digit span forward 
(raw)
Cortisol 0.757 0.184 0.345 0.515
DHEAS 0.814 0.446 0.662 0.481
Cortisol:DHEAS 0.421 0.348 0.221 0.559
Working Memory
Digit span 
backward (raw)
Cortisol 0.985 0.462 0.974 0.251
DHEAS 0.717 0.111 0.608 0.114
Cortisol:DHEAS 0.726 0.786 0.833 0.556
Letter number 
sequencing (raw)
Cortisol 0.114 0.881 0.055 0.658
DHEAS 0.810 0.173 0.659 0.202
Cortisol:DHEAS 0.259 0.221 0.319 0.157
Verbal Learning and Memory
Immediate PAL 
total
Cortisol 0.877 0.436 0.397 0.559
DHEAS 0.026 0.393 0.046 0.458
Cortisol:DHEAS 0.227 0.706 0.114 0.384
Delayed PAL total Cortisol 0.910 0.392 0.304 0.877
DHEAS 0.910 0.167 0.758 0.173
Cortisol:DHEAS 0.891 0.893 0.510 0.669
PAL=paired associate learning; DHEAS=sulphate dehydroepiandrosterone
